Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Sales reflect continued strong growth in oncology and vaccines
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
Submission based on results from pivotal phase III trial showing all primary endpoints met
Subscribe To Our Newsletter & Stay Updated
